Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
Christina Crossette-Thambiah, Haematology Specialist Registrar and Clinical Research Fellow at Imperial College London, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, published in Blood Advances, adding:
“It took us a very long time.
Having presented this work at ASH back in 2022 for various reasons it has taken a long time to see this to publication!
Big thank you to Professor Deepa Arachchillage, Prof Mike Laffan, HaemSTAR and the 15 NHS Trusts that contributed to one of the largest studies to date in Antiphospholipid Syndrome.
I want to make special mention of the late Richard Szydlo, senior biostatistician at Imperial College London who performed the initial analysis and then worked tirelessly to do further analysis even whilst in the midst of a very challenging time in his life.
A remarkable and generous individual.”
Title: Anticoagulation, recurrent thrombosis, and major bleeding in antiphospholipid syndrome: UK multicenter observational study
Authores: Christina Crossette-Thambiah, Indika Rajakaruna, Zain Odho, Andrew J. Doyle, Karen A. Breen, Michael Laffan, Deepa J. Arachchillageaborators
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk
-
Sep 9, 2026, 15:39Alessandro Lucchesi: The Future of MPN Disease Modification